Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lowe`s Companies Inc (LOW) vs 10X Genomics Inc (TXG) Price & Performance

Lowe`s Companies IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Lowe`s Companies Inc vs 10X Genomics Inc — how do they compare? Lowe`s Companies Inc trades at $221.48 (market cap $122.73B), while 10X Genomics Inc trades at $58.86 (market cap $7.64B). The key difference: Lowe`s Companies Inc is far larger — about 16.1× 10X Genomics Inc's market cap, and Lowe`s Companies Inc pays a 2.28% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

LOWTXG
Market Cap
$122.73B$7.64B
Sector
Consumer CyclicalHealth
52-Week High
$287.39$58.57
52-Week Low
$201.92$11.34
Enterprise Value
$164.48B$7.17B
Dividend Yield
2.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lowe`s Companies Inc

Lowe's (LOW) trades at $223.35, up 2.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $257.69. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Fundamentals show solid profitability with a net income margin of 7.51% and a P/E ratio of 18.88, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights mixed sentiment, with some institutional selling but optimism around the Pro business segment.

The outlook for LOW is cautiously optimistic, supported by strong analyst buy ratings (60.79%) and a dividend payout. Key risks include competitive pressures, macroeconomic sensitivity, and high debt levels. The upcoming Q2 earnings report on August 19, 2026, will be critical for validating growth expectations and could drive near-term price movement.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lowe`s Companies Inc

Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.

Read more on LOW

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG